Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 2
Submit an article Journal homepage
126
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia

Danqing Konga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaORCID Iconhttps://orcid.org/0000-0002-0816-4523View further author information
ORCID Icon,
Yun Lia National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Chengcheng Fua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Mengjia Houa National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;d Soochow Hopes Hematology Hospital, Suzhou, ChinaView further author information
,
Lingzhi Yana National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Jingjing Shanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Zhaoyue Wanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
,
Jie Yina National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaCorrespondence[email protected]
View further author information
,
Ziqiang Yua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
&
Depei Wua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;b Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Suzhou University, Suzhou, China;c Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, ChinaView further author information
 show all
Pages 491-494 | Received 13 Sep 2021, Accepted 08 Oct 2021, Published online: 20 Oct 2021

References

  • Federici AB, Rand JH, Bucciarelli P, et al. Acquired von willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84(2):345–349.
  • Tiede A, Rand JH, Budde U, et al. How I treat the acquired von willebrand syndrome. Blood. 2011;117(25):6777–6785.
  • Federici AB, Budde U, Castaman G, et al. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost. 2013;39(2):191–201.
  • Niiya M, Niiya K, Takazawa Y, et al. Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus. Blood Coagul Fibrinolysis. 2002;13(4):361–365.
  • Howard CR, Lin TL, Cunningham MT, et al. IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome. Blood Coagul Fibrinolysis. 2014;25(6):631–633.
  • Colella MP, Duarte GC, Marques JF, Jr, et al. Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome. Haemophilia. 2012;18(3):e188–e191.
  • Franchini M, Mannucci PM. Acquired von Willebrand syndrome: focused for hematologists. Haematologica. 2020;105(8):2032–2037.
  • Charlebois J, Rivard GE, St-Louis J. Management of acquired von willebrand syndrome. Transfus Apher Sci. 2018;57(6):721–723.
  • Gavva C, Patel P, Shen YM, et al. A case of autoimmune severe acquired von willebrand syndrome (type 3-like). Transfus Apher Sci. 2017;56(3):431–433.
  • Sieg AC, Moretz JD, Horn E, et al. Pharmacotherapeutic management of gastrointestinal bleeding in patients with Continuous-Flow left ventricular assist devices. Pharmacotherapy. 2017;37(11):1432–1448.
  • Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for waldenstrom macroglobulinaemia. Lancet Haematol. 2020;7(11):e827–e837.
  • Ojeda-Uribe M, Caron C, Itzhar-Baikian N, et al. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance. Am J Hematol. 2010;85(5):396.
  • Ojeda-Uribe M, Rimelen V, Marzullo C. Good profile of efficacy/tolerance of bortezomib or idelalisib in waldenström macroglobulinemia associated with acquired von willebrand syndrome. J Blood Med. 2020;11:67–72.
  • Hegerova L, He F, Zantek ND, et al. Reversal of acquired von Willebrand syndrome with allogeneic stem cell transplant for chronic lymphocytic leukemia. Blood Cells Mol Dis. 2019;77:109–112.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.